These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8212705)

  • 1. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine and lisuride infusion. A comparative chronic study.
    Stocchi F; Bramante L; Monge A; Viselli F; Baronti F; Stefano E; Ruggieri S
    Adv Neurol; 1993; 60():653-5. PubMed ID: 8420205
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
    Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
    Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Apomorphine in Parkinson disease].
    Gilhus NE
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3166-9. PubMed ID: 1948940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
    Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.